31 August 2022

At the meeting of 2 August 2022 the RMA:

Determined Statements of Principles (SOPs) for:

Condition SOPs
mature B-cell lymphoid leukaemia and small lymphocytic lymphoma 78/2022 79/2022
Creutzfeldt-Jakob disease 80/2022 81/2022
malignant neoplasm of the anus and anal canal 82/2022 83/2022
epilepsy 84/2022 85/2022
steatohepatitis 86/2022 87/2022

Note: 

  • The investigation concerning 'chronic lymphocytic leukaemia/small lymphocytic lymphoma' has resulted in the determination of Statements of Principles concerning mature B-cell lymphoid leukaemia and small lymphocytic lymphoma.

Determined Amendment Statements of Principles (SOPs) for:

Condition SOPs
allergic contact dermatitis 88/2022 89/2022
conjunctivitis 90/2022 91/2022
asthma 92/2022 93/2022
ankylosing spondylitis 94/2022 94/2022
anosmia 94/2022 94/2022
aortic aneurysm and aortic wall disorders 94/2022 94/2022
asthma 94/2022 94/2022
carotid artery disease 94/2022 94/2022
chronic pancreatitis 94/2022 94/2022
deep vein thrombosis 94/2022 94/2022
diabetes mellitus 94/2022 94/2022
giant cell arteritis 94/2022 94/2022
inflammatory bowel disease 94/2022 94/2022
malignant neoplasm of the cervix 94/2022 94/2022
malignant neoplasm of the kidney 94/2022 94/2022
non-aneurysmal aortic atherosclerotic disease 94/2022 94/2022
peripheral artery disease 94/2022 94/2022
psoriasis 94/2022 94/2022
pulmonary thromboembolism 94/2022 94/2022
renal artery atherosclerotic disease 94/2022 94/2022
retinal vascular occlusion 94/2022 94/2022
tinnitus 94/2022

The above SOPs take effect from 19 September 2022.

Decided to Undertake Consultation regarding:

Condition Reasons for Decision Date for Final Decision
atrial fibrillation and atrial flutter Intention to remove one or more factors December 2022
malignant neoplasm of the prostate Intention to remove one or more factors December 2022

Completed Investigations

The above determinations conclude the previously advertised investigations into: